^
    Back
    Association details:
    Biomarker:EGFR wild-type
    Cancer:Lung Adenocarcinoma
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma

    Excerpt:
    ...Histologically or cytologically confirmed of lung adenocarcinoma, EGFR wild-type or known drug-resistant mutation, stage IV or irradiative stage IIIB....
    Trial ID:
    NCT03376737
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

    Excerpt:
    ...Histologically/cytologically confirmed advanced/metastatic lung adenocarcinoma of stage IV with documented wild-type EGFR; 6....
    Trial ID:
    NCT02691871
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial

    Published date:
    02/01/2019
    Excerpt:
    This phase I trial was primarily conducted to determine the maximum tolerated dose (MTD) of apatinib combined with docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR who have failed to first-line platinum-based chemotherapy, and to evaluate the safety and tolerability of apatinib plus docetaxel....Apatinib plus docetaxel was well tolerated and showed promising efficacy in advanced lung adenocarcinoma.
    Secondary therapy:
    docetaxel
    DOI:
    10.1007/s10637-019-00735-1
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncotarget
    Title:

    Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

    Published date:
    09/12/2017
    Excerpt:
    In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally. 3 patients showed partial response and 8 patients showed stable diseases response to apatinib, with a medium progression-free survival (PFS) of 4.4 month (2-10 months). The objective remission rate (ORR) was 18.75%(3/16). The total disease control rate (DCR) was 68.75% (11/16).
    DOI:
    10.18632/oncotarget.19908